Supplementary Figure S1 from A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Year: 2023
Type: supplementary-materials
Abstract: Change in intracranial (Panel A) and extracranial (Panel B) tumor size and best overall response, and duration of exposure to abemaciclib (Panel C) in cohort B (HR+, HER2+ MBC). Note: Patients who did not have a post-baseline scan (for intracranial), or who did not have an extracranial lesion or a post-baseline scan (for extracranial) are not shown on waterfall plots. oIndicates patient received prior whole brain radiotherapy. +Indicates patient received prior stereotactic radiosurgery. #Indicates patient received concomitant endocrine therapy. ^Indicates patient received concomitant trastuzumab. Abbreviations: CR, complete response; HER2+/â^', human epidermal growth factor receptor-2 positive/negative; HR+, hormone receptor positive; MBC, metastatic breast cancer; NE, not estimable; PD, progressive disease; PR, partial response; SD, stable disease.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361888914